Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is a biopharmaceutical company focused on RNA-targeted therapeutics, with its sole political signal being a disclosed dividend-generating stock holding by former President Donald J. Trump.
BusinessWhat IONS does
Ionis Pharmaceuticals develops and commercializes RNA-targeted therapeutics, primarily for rare diseases. Its revenue is derived from collaborative R&D agreements, royalties, and product sales from partnered and wholly-owned drugs. The company's pipeline is heavily dependent on clinical trial outcomes and regulatory approvals from agencies like the FDA.
12 months past · 3 months futureIONS activity timeline
Executive Branch ConflictsIONS held by Trump-administration officials
Lifetime Government AwardsIONS federal contracts
IONS doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding IONS
Congressional TradesWho in Congress is trading IONS
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting IONSLive legislation impacting this stock
Political ProfileWhere IONS sits in Washington
[object Object]
STRUCTURAL: No lobbying spend (`get_political_influence.lobbying.total_income: 0`), no donations, and no federal contracts (`get_government_precedent.federal_contracts_summary: null`). EVIDENTIARY: One executive branch holding (`get_executive_branch_exposure.by_ticker[0].holdings[0].filer: Donald J. Trump`) with minimal reported value ('None (or less than $1,001)'), zero corporate insider buys in 180 days (`get_corporate_insider_signal.total_buys: 0`), and zero congressional traders. Net: Minimal direct political footprint.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
General legislative pressure on drug pricing and reimbursementCongress, HHS"Eight recent healthcare bills identified in `Recent bill_impacts` with non-zero impact_ratios."
Regulatory opportunities
-
Potential for favorable orphan drug or accelerated approval pathwaysFDA"Inferred from primary industry and sector, but no specific carveouts in `Recent bill_carveouts`."
Live signals + predictions for IONS — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades IONS
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord